

Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants from NASH

PITCH VIDEO INVESTOR PANEL



corvidane.com New York, NY



Minority Founder Biotech

LEAD INVESTOR



Rene Braeckman

I invested in Corvidane and agreed to be the lead investor because of the leadership's ambitious mission to develop a novel, safe drug to prevent heart attacks, strokes, and liver transplants from NASH, with a high chance of success because of the solid scientific rationale behind the product in these indications with an unmet medical need. A second very important reason for my interest in contributing to Corvidane is that the leadership team has strong domain expertise and previous operating experience. I expect this to lead to a better treatment for patients and financial benefits for investors.

Invested \$1,000 this round & \$26,000 previously

Highlights

- 1 CEO designed trials for Vascepa®, which reduces heart attack and stroke risk for high triglycerides.
- 2 Results of Corvida™'s effect on LDLr-/- mouse and genes associated with atherosclerosis due in 2023
- 3 Funds raised will lead to PreIND meetings with the FDA to ensure acceptability of human trials.
- 4 Corvida™'s components are designated GRAS (Generally Regarded as Safe) by the FDA.
- 5 Corvida™ is protected by patents in the US and Japan and are owned by the company.
- 6 This is an opportunity to impact global health and potentially realize significant financial gains.*
- 7 *Projections cannot be guaranteed.

Our Team



Paresh Soni CEO

20+ years of executive pharmaceutical experience in Cardiovascular diseases and NASH that includes Amarin, Alexion, Pfizer and Albireo. Led the NDA submission and approval of Vascepa®, designed and launched the landmark REDUCE-IT study.



Damion Boyer Co-Founder / COO

6 years experience as CEO of Corvidane. Responsible for initiating Corvidane's NASH program and forging strategic alliances in the U.S. and Europe, which includes UMC Utrecht and resulted in a non-dilutive subsidy from the Dutch government.



Peggy (Berry) Durst VP of Regulatory

28 years of Regulatory experience that includes 5 years with Amarin. Developed and operationalized FDA Regulatory strategy for Vascepa®, Managed clinical trial submissions in the U.S., the EU and Canada.



Patrice BINAY VP of Chemistry and CMC

32 years of pharmaceutical Fine Chemistry experience. Synthesis and analytical characterization of Active Pharmaceutical Ingredients, Quality auditing, Industrial Transfer. Development of a new class of anti-inflammatory (H4 Receptor).



Menno Van Burken VP of Commercial Strategy

32 years of pharmaceutical experience that includes 17 years with Pfizer. Lead Cardiovascular and Metabolic therapeutic disease initiatives across R&D, Clinical Development, Medical Affairs, Regulatory and Commercial functions.



John Burke Co-Founder and Adviser

Inventor of Corvida™ with 46 years Chemical Engineering expertise



Bill Sasiela



John Burke

Pitch



PROBLEM

Diseases of lipid metabolism + inflammation

Atherosclerosis



The buildup of **fat and cholesterol** (i.e., plaque) in artery walls that, when accompanied by inflammation, obstructs blood flow.

A major factor in **heart attacks and strokes**, the leading causes of death globally.

Nonalcoholic Steatohepatitis




An accumulation of excess **liver fat** accompanied by inflammation and cell damage, which can cause fibrosis and lead to cirrhosis and liver cancer.

NASH affects 5% of U.S. adults and is the leading cause of liver transplants in the U.S.

SOLUTION


A drug that can improve lipid metabolism, reduce inflammation and is safe.

Corvida™ contains two fatty acids: an Omega-7 and an Omega-9. Both are Generally Recognized as Safe (GRAS) by the FDA.




SOLUTION

Palmitoleic Acid (Omega-7)



Oleic Acid (Omega-9)



SOLUTION

We selected Omega-7s and Omega-9s that improve lipid metabolism and have anti-inflammatory properties to maximize the health benefit via multiple pathways.




Omega-7 and Omega-9 fatty acids are smaller and more capable of entering cells than Omega-3s.

Fatty Acid	Omega	Size	Double Bonds
Palmitoleic	7	16 Carbon Atoms	1
Oleic	9	18 Carbon Atoms	1
EPA	3	20 Carbon Atoms	5
DHA	3	22 Carbon Atoms	6

Omega-7 and Omega-9 fatty acids have fewer double bonds (Mono-unsaturated) and are less easily oxidized or otherwise damaged.

Corvida™ is an Omega-3 fatty acid drug, which is often used to reduce triglyceride levels in the body.



COMPETITION

ATHEROSCLEROSIS

AMARIN
Vascepa® (icosapent ethyl)

- Purified Eicosapentaenoic Acid (EPA), an omega-3 fatty acid, not Monounsaturated
- Originally approved to lower triglycerides
- Shows most potential of approved drugs to treat atherosclerosis (EVAPOHATE study)
- Does not provide benefit in NASH

NASH

northsea
Icosabutate

- Modified Eicosapentaenoic Acid (EPA), an omega-3 fatty acid, not Monounsaturated
- Currently in Phase 2 human studies targeting NASH patients with F2-F3 fibrosis
- Reduces triglyceride levels, but may increase LDL cholesterol levels

M&A ACTIVITY



Forward-looking projections cannot be guaranteed.

VALIDATION

Corvida™ studies have shown promising results

- University of Michigan**: Ability to treat Atherosclerosis and NASH simultaneously in the LDLr-/- mouse model (awaiting results)
- Cleveland Clinic**: Reduction in Atherosclerotic Plaque in the ApoE-/- mouse model
- Case Western Reserve University**: Improved metabolic processing of lipids in rodent model
- University of Michigan**: Effects on Atherogenic Lipids in Humans
- TNO**: Effects on Atherogenic Lipids in ApoE3 mouse model

INTELLECTUAL PROPERTY

Intellectual Property

Patents to treat Atherosclerosis Issued:

- uspto** • The United States
- 特許庁** • Japan
- INPI** • Brazil


...w/ applications pending in The EU, China, India and Canada.

• NASH provisional application filed in the U.S.

TEAM


<p>Dr. Parson Scott, MD, PhD – CEO & Chief Medical Officer An expert in NASH with 20+ years executive pharmaceutical experience, including Amarin, Novartis, Pfizer and AbbVie. Led FDA approval of Vascepa®.</p>	<p>Damion J. Boyer – Co-Founder & COO Former Convidone CEO. Initiated Convidone's NASH program and forged strategic alliances in Europe.</p>
<p>Patrice Berry, PhD – Vice President of Chemistry and Manufacturing 34 years of pharmaceutical fine chemistry experience.</p>	<p>Maria Van Buren, Ph.D. – Vice President of Commercial Strategy 35 years of pharmaceutical experience, including 17 years with Pfizer.</p>
<p>John M. Burke – Co-Founder and Inventor of Corvida™ 47 years of Chemical Engineering experience.</p>	

OFFERING



Only \$618k of the \$5M will be solicited through this Wefunder offering. Also, forward-looking projections cannot be guaranteed.

- Low valuation for early investors with potential for upside with 2 large indications
- Potential to treat millions of patients with common metabolic diseases



RESEARCH

Proof of Concept: Effects on Atherosclerosis in Rodents

The Cleveland Clinic

Mouse Atherosclerosis Progression Study

- Examined the effects Corvida™ (GOC) diet vs. Western Diet in ApoE^{-/-} mice; a well-established model for atherosclerosis progression
- Corvida™ diet replaced 20% standard Western diet fat with Corvida™:
- Increased HDL cholesterol by 77% compared to the control group
- Reduced triglycerides by 11% compared to control group
- Produced significant reductions in atherosclerosis

• Effect on atherosclerosis versus atherogenic lipid suggests beneficial effects beyond lipids

Table 2.	Aortic sinus lesion size (mm ²)	
Corvida™	Control	Treatment
	0.33 ± 0.09	0.18 ± 0.07**

Table 3.	Aortic lesion (%)	
Corvida™	Control	Treatment
	9.83 ± 2.8	3.17 ± 1.5**
†Flouxvastatin (20mg/kg/day) ²	21.9 ± 2.9	11.9 ± 1.9*

^{*}Compared to the Control group. ^{**}p<0.05, ^{††}p<0.001.
†††From S. Sano et al., J. Lipid Res. 2014. *Macadamia nut oil diet vs. standard Western diet in ApoE^{-/-} mice. Atherosclerosis progression in ApoE^{-/-} mice. Atherosclerosis progression in ApoE^{-/-} mice. Atherosclerosis progression in ApoE^{-/-} mice.

RESEARCH

Improved Metabolic Processing of Lipids

Case Western Reserve University

Study of Corvida™ in an Animal Model

- Double blind, 8-week study of 18 Sprague Dawley rats receiving 50% of calories from fat to resemble typical American diet (40%-45% of calories from fat). Three arms of 6 rats each:
1. Corvida™ Diet
 2. Saturated Fat Diet - Lauric acid (C12:0) and Myristic acid (C14:0)
 3. Oleic acid (C18:1)

Lead Investigator: Dr. Charles Hoppel, M.D.

- Results/Conclusions:**
- Corvida™'s constituents absorbed into the blood and heart, liver and adipose tissue
 - Corvida™ improves metabolic processing of lipids and glucose resulting in reduced liver fat accumulation and sustained liver function.


RESEARCH

Improved Metabolic Processing of Lipids

Case Western Reserve University

Study of Corvida™ in an Animal Model

Analysis reveals the statistical and physical evidence of Corvida™'s ability to improve metabolic function:



RESEARCH

Proof of Concept: Proof of Concept Effects on Atherogenic Lipids in Humans

The University of Hawaii

Human Dietary Study

- Used macadamia nuts (high in oleic and palmitoleic acids) compared to typical Western diet
- Subjects were relatively healthy volunteers with well-controlled lipids at baseline (mean baseline LDL-C levels of 130 mg/dl; mean baseline TGs of 80 mg/dl)
- With macadamia nut diet:
 - LDL-C was 5.9 mg/dl lower than American diet (p<0.05)
 - TGs were 7.1 mg/dl lower than American diet (p<0.05)
 - Non-HDL-C is calculated to be 7.4 mg/dl lower than American diet
- Macadamia nut diet was safe and well-tolerated

RESEARCH



Proof of Concept: Effects on Atherogenic Lipids in Rodents

TNO ApoE3* Leiden Mouse Model Lipids Study

- ApoE3* Leiden mouse model is a well-established and validated model for human dyslipidemia and progression of atherosclerosis
- Marteik algae oil was tested to western diet. Specifically, 6% Marteik algae oil replaced 6% of cacao butter in the Western diet (which is 15% cacao butter).
- Marteik algae oil is highly enriched in palmitoleic acid and palmitic acid
- As compared to Western diet, Marteik algae oil at 4 weeks
 - Reduced total cholesterol by 37%
 - Reduced TGs by 44%



Corvidane

THANK YOU

"We will meet the challenge." – Dr. Oheneba Boachie-Adjet

paresh@Corvidane.com
damion@Corvidane.com